Management of overactive bladder review: the role of percutaneous tibial nerve stimulation

Elita Wibisono, Harrina E. Rahardjo



Overactive bladder (OAB) is a common condition that is experienced by around 455 million people (11% of the world population) and associated with significant impact in patients’ quality of life. The first line treatments of OAB are conservative treatment and anti-muscarinic medication. For the refractory OAB patients, the treatment options available are surgical therapy, electrical stimulation, and botulinum toxin injection. Among them, percutaneous tibial nerve stimulation (PTNS) is a minimally invasive option that aims to stimulate sacral nerve plexus, a group of nerve that is responsible for regulation of bladder function. After its approval by food and drug administration (FDA) in 2007, PTNS revealed considerable promise in OAB management. In this review, several non-comparative and comparative studies comparing PTNS with sham procedure, anti-muscarinic therapy, and multimodal therapy combining PTNS and anti-muscarinic had supportive data to this consideration.


electrical stimulation overactive bladder; percutaneous tibial nerve stimulation

Full Text:



  1. Payne CK. Conservative Management of Urinary Incontinence: Behavioral and Pelvic Floor Therapy, Urethral and Pelvic Devices. In: Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 1. 10th ed. Philadelphia: Elsevier Saunders; 2012. p. 2026–46.
  2. Staskin D, Kelleher C, Bosch R, Cotterill N, Coyne K, Kopp Z, et al. Initial assessment of urinary incontinence in adult male and female patients. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence: 5th International Consultation on Incontinence. France: ICUD-EAU; 2013. p. 361–88.
  3. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P, et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourology and urodynamics. 2009;28(4):287.
  4. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourology and urodynamics. 2002;21(2):167–78.
  5. Sumardi R, Mochtar CA, Junizaf, Santoso BI, Setiati S, Nuhonni SA, et al. Prevalence of urinary incontinence, risk factors and its impact: multivariate analysis from indonesian nationwide survey. Acta medica Indonesiana. 2014;46(3):175–82.
  6. Percutaneous tibial nerve stimulation for the treatment of overactive bladder [Internet]. California Technology Assessment Forum. 2012 [cited June 20, 2012]. Available from: June 2012_0.pdf.
  7. Drake M, Abrams P. Overactive bladder. In: Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 1. 10th ed. Philadelphia: Elsevier Saunders; 2012. p. 1947–56.
  8. Banakhar MA, Al-Shaiji TF, Hassouna MM. Pathophysiology of overactive bladder. International urogynecology journal. 2012;23(8):975–82.
  9. Steers WD. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol. 2002;4(Suppl 4):S7-18.
  10. Vasavada SP, Rackley RR. Electrical stimulation and neuromodulation in storage and emptying failure. In: Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 1. 10th ed. Philadelphia: Elsevier Saunders; 2012. p. 2026–45.
  11. Chu FM, Dmochowski R. Pathophysiology of overactive bladder. The American journal of medicine. 2006;119(3):3–8.
  12. Abrams P, Andersson K, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourology and urodynamics. 2010;29(1):213–40.
  13. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. European urology. 2005;48(1):5–26.
  14. Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstetrics & Gynecology. 2008;112(6):1311–8.
  15. Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. International journal of clinical practice. 2011;65(5):567–85.
  16. Brostrom S, Hallas J. Persistence of antimuscarinic drug use. European journal of clinical pharmacology. 2009;65(3):309–14.
  17. Tanagho EA, Bella AJ, Lue TF. Neuropathic bladder disorders. In: Tanagho EA, McAninch JW, editors. Smith's general urology. 17th ed. New York: McGraw-Hill Medical; 2008. p. 438–54.
  18. Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. The Cochrane Library. 2009.
  19. Burton C, Sajja A, Latthe P. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: A systematic review and meta‐analysis. Neurourology and urodynamics. 2012;31(8):1206–16.
  20. Gungor Ugurlucan F, Onal M, Aslan E, Ayyildiz Erkan H, Kizilkaya Beji N, Yalcin O. Comparison of the effects of electrical stimulation and posterior tibial nerve stimulation in the treatment of overactive bladder syndrome. Gynecologic and obstetric investigation. 2013;75(1):46–52.
  21. Govier FE, Litwiller S, Nitti V, Kreder KJ, Rosenblatt P. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. The Journal of urology. 2001;165(4):1193–8.
  22. van der Pal F, Heesakkers JP, Bemelmans BL. Current opinion on the working mechanisms of neuromodulation in the treatment of lower urinary tract dysfunction. Current opinion in urology. 2006;16(4):261–7.
  23. Chen Y-F, Bramley G, Unwin G, Dretzke J, Moore D, Hanu-Cernat D. Systematic Reviews referred by the NICE Interventional Procedures Programme on behalf of the NICE Interventional Procedures Advisory Committee (IPAC) Title Stimulation of peripheral nerves for the treatment of refractory pain (including peripheral nerve field. 2012.
  24. Lucas M, Bedretdinova D, Bosch J, Burkhard F, Cruz F, Nambiar A, et al. EAU guidelines of urinary incontinence. 2013.
  25. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. The Journal of urology. 2012;188(6):2455–63.
  26. MacDiarmid SA, Staskin DR. Percutaneous tibial nerve stimulation (PTNS): a literature-based assessment. Current Bladder Dysfunction Reports. 2009;4(1):29–33.
  27. Van Balken M, Vergunst H, Bemelmans B. Prognostic factors for successful percutaneous tibial nerve stimulation. European urology. 2006;49(2):360–5.
  28. Nuhoğlu B, Fidan V, Ayyıldız A, Ersoy E, Germiyanoğlu C. Stoller afferent nerve stimulation in woman with therapy resistant over active bladder; a 1-year follow up. International urogynecology journal. 2006;17(3):204–7.
  29. Van Der Pal F, Van Balken MR, Heesakkers JP, Debruyne FM, Bemelmans BL. Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary? BJU international. 2006;97(3):547–50.
  30. Finazzi Agro E, Campagna A, Sciobica F, Petta F, Germani S, Zuccala A, et al. Posterior tibial nerve stimulation: is the once-a-week protocol the best option? Minerva urologica e nefrologica = The Italian journal of urology and nephrology. 2005;57(2):119–23.
  31. Karademir K, Baykal K, Sen B, Senkul T, Iseri C, Erden D. A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation. Scandinavian journal of urology and nephrology. 2005;39(3):230–3.
  32. Finazzi Agro E, al. e. Percutaneous tibial nerve stimulation (PTNS) in the treatment of urge incontinence: A double blind placebo controlled study. SIUD National Congress; Italy: Uroplasty; 2005.
  33. Finazzi-Agrò E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. The Journal of urology. 2010;184(5):2001–6.
  34. Finazzi‐Agrò E, Rocchi C, Pachatz C, Petta F, Spera E, Mori F, et al. Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials. Neurourology and urodynamics. 2009;28(4):320–4.
  35. Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. The Journal of urology. 2010;183(4):1438–43.
  36. Wibisono E, Rahardjo HE. Effectiveness of short term percutaneous tibial nerve stimulation for non-neurogenic overactive bladder syndrome in adults: a systematic review and meta analysis. Acta Med Indones. 2015;47(3):188-200.
  37. Souto SC, Reis LO, Palma T, Palma P, Denardi F. Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome. World journal of urology. 2014;32(1):179–84.
  38. Peters KM, MacDiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. The Journal of urology. 2009;182(3):1055–61.
  39. Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. Gynecologic and obstetric investigation. 2012;75(4):230–4.
  40. Sancaktar M, Ceyhan ST, Akyol I, Muhcu M, Alanbay I, Mutlu Ercan C, et al. The outcome of adding peripheral neuromodulation (stoller afferent neuro-stimulation) to anti-muscarinic therapy in women with severe overactive bladder. Gynecological Endocrinology. 2010;26(10):729–32.
  41. Kabay SC, Kabay S, Yucel M, Ozden H. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson's disease. Neurourology and urodynamics. 2009;28(1):62–7.
  42. Gobbi C, Digesu G, Khullar V, El Neil S, Caccia G, Zecca C. Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicentre, prospective, open label trial. Multiple Sclerosis Journal. 2011;17(12):1514–9.
  43. De Gennaro M, Capitanucci M, Mastracci P, Silveri M, Gatti C, Mosiello G. Percutaneous tibial nerve neuromodulation is well tolerated in children and effective for treating refractory vesical dysfunction. The Journal of urology. 2004;171(5):1911–3.
  44. Hoebeke P, Renson C, Petillon L, Walle JV, De Paepe H. Percutaneous electrical nerve stimulation in children with therapy resistant nonneuropathic bladder sphincter dysfunction: a pilot study. The Journal of urology. 2002;168(6):2605–8.
  45. MacDiarmid SA, Peters KM, Shobeiri SA, Wooldridge LS, Rovner ES, Leong FC, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. The Journal of urology. 2010;183(1):234–40.
  46. Peters KM, Carrico DJ, MacDiarmid SA, Wooldridge LS, Khan AU, McCoy CE, et al. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24‐month results of the STEP study. Neurourology and urodynamics. 2013;32(1):24–9.
  47. Peters K, Carrico D, editors. Percutaneous tibial nerve stimulation for the treatment of overactive bladder syndrome: final 36-month results of the STEP study. Neurology and Urodynamics; 2013: Wiley-Blackwell.

Copyright (c) 2017 Elita Wibisono, Harrina E. Rahardjo

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All articles and issues in Medical Journal of Indonesia have unique DOI number registered in Crossref.